Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China
Abstract Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg w...
Main Authors: | Xin Nie, Yulong Wang, Hong Yi, Yanbin Qiao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12886-021-01877-8 |
Similar Items
-
Short-term effects of intravitreal Conbercept for choroidal neovascularization secondary to high myopia
by: Jie-Yun He, et al.
Published: (2018-12-01) -
Curative effect of compound Xuesaitong combined with Conbercept in the treatment of choroidal neovascularization in pathological myopia
by: He-Ling Huang, et al.
Published: (2017-06-01) -
Outcomes of Conbercept therapy for choroidal neovascularization secondary to pathological myopia
by: Zheng-Feng Liu, et al.
Published: (2020-12-01) -
Effect analysis of the intravitreal Conbercept in the treatment of choroid neovascularization of macular with high myopia
by: Hui-Xuan Ren, et al.
Published: (2021-06-01) -
Macular hole retinal detachment after intravitreal Conbercept injection for the treatment of choroidal neovascularization secondary to degenerative myopia: a case report
by: Chuan-bin Sun, et al.
Published: (2019-07-01)